AMAriane Paz Y Miño

Ariane Paz Y Miño

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ariane Paz Y Miño has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pseudomonas aeruginosa epidemic high-risk clones and their association with multidrug-resistant

    by Jeannete Zurita, Gabriela Sevillano, María Belén Solís, Ariane Paz Y Miño, Beatriz Rizkallah Alves, Jessica Changuan, Pablo González


  • Open Access

    Utilidad del análisis filogenético de la región espaciadora interna transcrita (ITS) para la diferenciación de especies del complejo Candida parapsilosis

    by Jeannete Zurita, Gabriela Sevillano, Samantha Sáenz Hinojosa, Ariane Paz Y Miño, Camilo Zurita-Salinas

    Candida parapsilosis complex includes Candida parapsilosis sensu stricto, Candida orthopsilosis, Candida metapsilosis, which are phenotypically indistinguishable from each other. They show differences in virulence, susceptibility to antifungals and epidemiology. This study aimed to evaluate the phylogenetic analysis using ITS gene sequences from clinical isolates, collected between 2018 to 2023, as a new diagnostic tool for the identification of these species. A total of 84 yeasts were studied from patients between 0 and 96 years old. Male patients were the most affected. They were isolated most frequently from blood, ear secretions, skin, and soft tissues. Candidemia was an important clinical entity in children under 1 year of age and in the group of adults from 20 to 65 years of age. Through phylogenetic analysis, C. parapsilosis sensu stricto was identified in 74 isolates, C. orthopsilosis in 7 isolates and 3 C. metapsilosis in 3 isolates. The use of phylogenetic trees as a diagnostic tool allowed to distinguish the members of the Candida parapsilosis complex, by analyzing similarities between the sequences of the ITS region. For the management of the infection caused by these species the appropriate identification is required. El complejo Candida parapsilosis está compuesto por Candida parapsilosis sensu estricto, Candida ortopsilosis, Candida metapsilosis, que son fenotípicamente indistinguibles entre sí. Presentan diferencias en virulencia, susceptibilidad a antifúngicos y epidemiología. Este estudio tuvo como objetivo evaluar el análisis filogenético utilizando secuencias del gen ITS de aislados clínicos, recolectados entre 2018 al 2023, como una nueva herramienta diagnóstica para la identificación de estas especies. Un total de 84 levaduras fueron descongeladas de pacientes entre 0 a 96 años. Los pacientes de sexo masculino fueron los más afectados. Se aislaron con mayor frecuencia de sangre, secreciones óticas, piel anexos y tejidos blandos y secreciones óticas. La candidemia fue una entidad clínica importante en menores de 1 año y en el grupo de adultos de 20 a 65 años. Mediante el análisis filogenético se llegó a la identificación C. parapsilosis sensu estricto en 74 aislamientos, C. orthopsilosis en 7 aislamientos y 3 C. metapsilosis en 3 aislamientos. El uso de árboles filogenéticos como herramienta diagnóstica nos permitió distinguir los miembros del complejo Candida parapsilosis, mediante el análisis de similitudes entre las secuencias de la región ITS. Se plantea la necesidad de la identificación de estas tres especies para el manejo clínico y epidemiológico.


  • Open Access

    226. Low incidence of Pseudomonas species in Gram negative blood stream infections in nine hospitals across Ecuador: an unexpected find

    by Jeannete Zurita, Gabriela Sevillano, Maria Belen Solis, Ariane Paz Y Miño, Beatriz Rizkallah Alves, Camilo Zurita-Salinas, Ecuadorian Bacteremia

    Over the last years, several studies on bloodstream infections (BSI) have ranked P. aeruginosa in the top 5 list of Gram-negative causal agents. However, there is very limited data regarding the incidence of Pseudomonas bacteremia in Latin America. The aim of this study was to establish the incidence of bacteremia caused by Pseudomonas species During the period from November 2021 to May 2022 in 9 hospitals in Ecuador, blood culture samples were taken according to the clinical requirements of each patient. The bacteria identification was carried out using automated system (Vitek2 and Phoenix1000) and was confirmed by proteomic (MALDITOF) and molecular sequencing. Antimicrobial susceptibility was performed according to CLSI 2021. This study provided relevant information on BSI caused by Pseudomonas in Ecuador.There are only few population-based studies evaluating bacteremia epidemiology in Latin America. SENTRY in 1997 estimated that P. aeruginosa contributed to 10.6% of gram-negative nosocomial and community-acquired bloodstream infections. Lower incidence levels, as seen in this study (0.043%), could help better understand population trends and help guide treatment. Jeannete Zurita, n/a, Pfizer: Grant/Research Support

  • Open Access

    Infección comunitaria del tracto urinario por Escherichia coli en la era de resistencia antibiótica en Ecuador

    by María Belén Solís, Silvana Romo, Mateo Granja, Juan José Sarasti, Ariane Paz Y Miño, Jeannete Zurita

    Las infecciones del tracto urinario (ITU) se encuentran entre las enfermedades infecciosas más frecuentes que afectan a los seres humanos y representan un importante problema de salud pública con una carga de morbilidad y de altos costos sanitarios especialmente cuando se complican. Los objetivos de este estudio son actualizar los patrones de resistencia a los antibióticos utilizados para las ITU causadas por E. coli comunitaria, comparar la resistencia antimicrobiana con otros datos publicados en Ecuador y sugerir varias estrategias para superar los desafíos que se presentan en el trabajo diario del laboratorio y la práctica clínica asociados con este importante problema. Resultados: Se aislaron 3341 Escherichia coli (79,38%), 299 Klebsiella pneumoniae (7,1%), 192 Enterococcus faecalis (4,56%), y otros microorganismos en el resto de muestras. Las alternativas de tratamiento empírico para E. coli son: nitrofurantoina, fosfomicina, amoxicilina/clavulanato, cefuroxima, ampicilina/sulbactam. E. coli productora de BLEE se encontró en 612 muestras (18,4%). Conclusión: es fundamental vigilar la resistencia bacteriana a nivel de comunidad, los datos obtenidos de la vigilancia hospitalaria no deben ser extrapolados a la comunidad.


  • Open Access

    Mutations associated with Helicobacter pylori antimicrobial resistance in the Ecuadorian population

    by Jeannete Zurita, Gabriela Sevillano, Ariane Paz Y Miño, Camilo Zurita-Salinas, Vicente Peñaherrera, Manuel Echeverría, Helicobacter pylori Research Group, Hugo Navarrete, María Ángeles Silva Casares, Ivonne Orellana Narvaez, et al.

    Aims We describe the presence of Helicobacter pylori (HP) and estimated the prevalence of primary and secondary resistance using molecular detection in gastric biopsies of Ecuadorian patients. Methods and Results A 66.7% (238/357) of the patients demonstrated the presence of HP using CerTest qPCR. Of these 69.79% (104/149) without previous HP eradication treatment and 64.42% (134/208) with prior HP eradication treatment. The mutation-associated resistance rate for clarithromycin was 33.64% (Primary resistance) and 32.82% (Secondary resistance). While that in levofloxacin the primary and secondary resistance was 37.38% and 42%, respectively. For tetracycline and rifabutin, primary and secondary resistance was 0%. Primary and secondary resistance for metronidazole and amoxicillin could not be evaluated by genotypic methods (PCR and sequencing). Conclusions The analysis of mutations in gyrA, 23S rRNA, and 16S rRNA is useful is useful to detect bacterial resistance as a guide for eradication therapy following failure of the first-line regimen. Significance and Impact of Study This study carried out in an Ecuadorian population indicates that the resistance of HP to first-line antibiotics is high, which may contribute to the high rates of treatment failure, and other treatment alternatives should be considered.